Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 11/20 | 0.48 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14419235 | 0.89 | CTSA (0.48) | CTSAKCNMA1SMPD3USP2 | |
| SCHEMBL12475399 | 0.85 | CTSA (0.47) | CTSASMPD3CHEK1 | |
| SCHEMBL4849102 | 0.75 | ALDH1A1 (0.38) | CTSAKCNMA1USP2CNR2 | |
| SCHEMBL29752075 | 0.73 | ACHE (0.52) | CTSA | |
| SCHEMBL4858097 | 0.73 | CNR2 (0.36) | KCNMA1CNR2 | |
| SCHEMBL759089 | 0.73 | CTSA (0.40) | CTSA | |
| SCHEMBL6011470 | 0.71 | FFAR2 (0.46) | CTSACNR2 | |
| SCHEMBL2616488 | 0.71 | KMT2A (0.51) | CTSA | |
| SCHEMBL6239164 | 0.71 | LPAR1 (0.44) | — | |
| SCHEMBL8309981 | 0.70 | CA1 (0.36) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CTSA 3810/4885KCNMA1 2141/4885SMPD3 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.